Antiviral activity of dolutegravir in subjects with failure on an integrase inhibitor-based regimen: week 24 phase 3 results from VIKING-3

被引：7
|
作者：
Nichols, G. [1 ]
Mills, A. [2 ]
Grossberg, R. [3 ]
Lazzarin, A. [4 ]
Maggiolo, F. [5 ]
Molina, J. [6 ]
Pialoux, G. [7 ]
Wright, D. [8 ]
Ait-Khaled, M. [9 ]
Huang, J. [10 ]
Vavro, C. [1 ]
Wynne, B. [11 ]
Yeo, J. [9 ]
机构：
[1] GlaxoSmithKline, Res Triangle Pk, NC USA
[2] Anthony Mills MD Inc, Los Angeles, CA USA
[3] Montefiore Med Ctr, New York, NY USA
[4] Ist Sci San Raffaele, I-20132 Milan, Italy
[5] Osped Riuniti Bergamo, I-24100 Bergamo, Italy
[6] Hosp St Louis, Paris, France
[7] Hosp Tenon, Paris, France
[8] Cent Texas Clin Res, Austin, TX USA
[9] GlaxoSmithKline, London, England
[10] GlaxoSmithKline, Mississauga, ON, Canada
[11] GlaxoSmithKline, Philadelphia, PA USA
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2012年 / 15卷
关键词：
D O I：
10.7448/IAS.15.6.18112
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：8 / 8
页数：1
相关论文
共 50 条
  • [31] Secukinumab Provides Significant Improvement of Spinal Pain and Lowers Disease Activity in Patients with Axial Spondyloarthritis: 24-week Results from a Randomized Controlled Phase 3b Trial
    Poddubnyy, Denis
    Pournara, Effie
    Zielinska, Agnieszka
    Baranauskaite, Asta
    Munoz Jimenez, Alejandro
    Sadhu, Sanchayita
    Schulz, Barbara
    Rissler, Michael
    Perella, Chiara
    Marzo-Ortega, Helena
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [32] STRIIVING: switching to abacavir/dolutegravir/lamivudine fixed dose combination (ABC/DTG/3TC FDC) from a PI, INI or NNRTI based regimen maintains HIV suppression at week 48
    Lake, J. E.
    Trottier, B.
    Garcia-Diaz, J.
    Edelstein, H.
    Kumar, P.
    Bredeek, U. F.
    Loutfy, M.
    Brennan, C.
    Koteff, J.
    Wynne, B.
    Hopking, J.
    Aboud, M.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
  • [33] Phase 3, randomised, controlled trial of switching to fixed-dose bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) from boosted protease inhibitor-based regimens in virologically suppressed adults: a sub-analysis of week-48 lipid results
    Fox, J.
    Post, F. A.
    Johnson, M.
    Daar, E. S.
    DeJesus, E.
    Liu, Y-P
    Graham, H.
    Cheng, A.
    Martin, H.
    Quirk, E.
    HIV MEDICINE, 2018, 19 : S84 - S85
  • [34] Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (52-Week) Improvement in Measures of Disease Activity in Patients with Psoriatic Arthritis: Results from 3 Phase 3, Randomized, Controlled Trials.
    Kavanaugh, Arthur
    Cutolo, Maurizio
    Mease, Philip
    Gladman, Dafna D.
    Adebajo, Adewale O.
    Gomez-Reino, Juan
    Wollenhaupt, Juergen
    Schett, Georg A.
    Lespessailles, Eric
    Hu, ChiaChi
    Stevens, Randall M.
    Edwards, Christopher
    Birbara, Charles A.
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S239 - S240
  • [35] Subcutaneous Tanezumab Versus Tramadol for Chronic Low Back Pain: Efficacy and Safety Results from a 56-Week Phase 3 Study with a 24-Week Follow Up Period
    Markman, John
    Bolash, Robert
    McAlindon, Timothy
    Kivitz, Alan
    Pombo-Suarez, Manuel
    Ohtori, Seiji
    Li, David
    Viktrup, Lars
    Bramson, Candace
    West, Christine
    Verburg, Kenneth
    NEUROLOGY, 2020, 94 (15)
  • [36] Ensifentrine Reduced Healthcare Resource Utilization in Subjects With COPD: Results From Enhance-2, a Phase 3 Trial of Ensifentrine, a Dual PDE3/4 Inhibitor
    Barjaktarevic, I.
    Rheault, T.
    Bengtsson, T.
    Rickard, K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [37] Cumulative response to guselkumab through week 24 of induction in patients with moderately to severely active ulcerative colitis: Results from the phase 3 QUASAR induction study
    Rubin, D.
    Sands, B.
    Lichtenstein, G.
    Baker, T.
    Huang, K. H.
    Germinaro, M.
    Miao, Y.
    Zhang, H.
    Nancey, S.
    Allegretti, J.
    Feagan, B.
    Hisamatsu, T.
    Panes, J.
    Dignass, A.
    Bressler, B.
    Peyrin-Biroulet, L.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1722 - I1723
  • [38] Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial
    Kristensen, Lars Erik
    Keiserman, Mauro
    Papp, Kim
    McCasland, Leslie
    White, Douglas
    Lu, Wenjing
    Wang, Zailong
    Soliman, Ahmed M.
    Eldred, Ann
    Barcomb, Lisa
    Behrens, Frank
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (02) : 225 - 231
  • [39] EFFICACY AND SAFETY OF BENRALIZUMAB IN ADULTS AND ADOLESCENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE 24-WEEK DOUBLE-BLIND PERIOD OF THE PHASE 3 MESSINA TRIAL
    Rothenberg, Marc E.
    Dellon, Evan S.
    Collins, Margaret H.
    Bredenoord, Albert J.
    Hirano, Ikuo
    Peterson, Kathryn A.
    Brooks, Laura
    Fjallbrant, Harald
    Grindebacke, Hanna K.
    Ho, Calvin N.
    Keith, Matthew
    McCrae, Christopher
    White, Wendy
    Datto, Catherine
    GASTROENTEROLOGY, 2023, 164 (06) : S114 - S115
  • [40] Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial
    Ostor, Andrew
    Van den Bosch, Filip
    Papp, Kim
    Asnal, Cecilia
    Blanco, Ricardo
    Aelion, Jacob
    Alperovich, Gabriela
    Lu, Wenjing
    Wang, Zailong
    Soliman, Ahmed M.
    Eldred, Ann
    Barcomb, Lisa
    Kivitz, Alan
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (03) : 351 - 358
12345